По вашему запросу найдено документов: 1005012
Страница 5 из 100502
Non-neutralizing antibodies directed at conservative influenza antigens) and neuraminidase (NA), as well as highly conserved antigens, such as M2 (ion channel), M1 (matrix protein), and NP
Vaccine prophylaxis during the covid-19 pandemic. Specific prevention of coronavirus infection technology platforms, including RNA and DNA vaccines, subunit recombinant, live-attenuated and viral vectors
Vaccines against african swine fever (review) immunization using purified proteins from infected cells or the recombinant proteins, and DNN constructs, p30
Encapsulation of Allergens into Core–Shell Chitosan Microparticles for Allergen-Specific Subcutaneous Immunotherapy administration of allergen extracts or recombinant proteins. The long duration of the treatment, the cost
COVID-19, Retroelements, and Aging recombination, or the virus can use retroelement proteins to integrate into the host genome. There is supporting
Cloning, expression, and purification of the nucleocapsid protein of SARS coronavirusCloning, expression, and purification of the nucleocapsid protein of SARS coronavirus
Recombinant viruses for cancer therapy© 2018 by the authors. Recombinant viruses are novel therapeutic agents that can be utilized
Nanoparticle vaccines against infectious diseases of existing vaccines against specific diseases. To date, some vaccines are developed from protein subunits
Recombinant live attenuated influenza vaccine viruses carrying conserved T-cell epitopes of human adenoviruses induce functional cytotoxic T-cell responses and protect mice against both infections recombinant LAIV-AdV vaccines by inserting the selected AdV T-cell epitopes into the open reading frame
Membrane microvesicles as potential vaccine candidates of social and public healthcare. The global impact of SARS-CoV-2 has demonstrated how outbreaks of emerging
Страница 5 из 100502
Фасеты
Партнеры
Индексация
